abstract |
The present invention relates to ophthalmic formulations containing tyrosine kinase inhibitors such as nintedinib, axitinib, sorafenib and pazopanib. Ophthalmic formulations may contain microparticles or nanoparticles of tyrosine kinase inhibitors. The present invention also relates to methods of using ophthalmic formulations for treating ocular surface diseases such as pterygium, including pterygium, and recurrent pterygium. |